Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
BIO
BIO
NYSE
Health Technology
Medical Specialties
305.96
USD
+4.26
+1.41%
Cerrado: 07-22 20:00 (UTC+0)
305.96
USD
+1.34
+0.44%
Premercado: 07-23 08:26 (UTC+0)

BIO Estadísticas clave

Alto
307.10
Abrir
301.00
Volumen
275.06K
Bajo
298.74
Cierre anterior
301.70
Valor negociado
84.03M
Máx. 52 sem.
343.12
Volumen rel.
0.897
Amplitud (%)
2.77%
Mín. 52 sem.
236.73
Tasa de rotación
1.27%
Cap. de Mercado
8.18B
PER (TTM)
50.37
PER (Anual)
10.978
P/B
1.2
P/S
3.16
Beneficio por acción (BPA)
6.075
Dividendo (TTM)
0
Rentabilidad por dividendo
0.00%
Acciones en circulación
21.70M
Moneda
USD

BIO Rendimiento del Precio

7 día
30 día
90 día
180 día
En lo que va del año
1 Año
BIO Distribución del flujo de dinero
BIO Volumen diario de ventas en corto
BIO Historial de short interest
As of 2026-07-23, the Bio-Rad Laboratories, Inc. (BIO) stock price today is 305.96. Based on this price, the company has a market capitalization of $8.18B, with a P/E ratio of 50.37. On 2026-07-23, BIO traded between 298.74 and 307.10. Today’s stock price is 2.42% above the daily low and 0.37% below the daily high, placing BIO de cerca del extremo superior de its most recent trading range. Trading volume currently stands at 275.06K, compared with an average daily volume of 306.76K. This suggests that trading activity is aproximadamente en línea con su nivel habitual than usual. Over the past year, Bio-Rad Laboratories, Inc. shares have traded between 236.73 and 343.12. At today’s price, BIO is 29.24% above its 52-week low and 10.83% below its 52-week high.
Nombre empresa
Bio-Rad Laboratories, Inc.
Sector
Health Technology
Industria
Medical Specialties
Intercambios
NYSE
Número de empleados
7,450
Tamaño del lote
40
Sitio oficial
Moneda
USD
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

BIO FAQ

Buscar divisas
Más